As pre-clinical research continues to uncover the relevance of this pathway to the progression of multiple tumor types, and to increasingly demonstrate its importance to aggressive tumor hallmarks in specific genetic backgrounds, there is compelling evidence to begin to evaluate anti-CXCL8 signaling inhibitors in human cancer. This evidence concerns the gene CXCL8 and cancer.